| Advanced gastric cancer (HER2+) |
Chemotherapy + Trastuzumab |
61 |
DpR ≥45% vs. <45%, mPFS [9.0 vs. 6.3 months, HR =0.608 (95% CI: 0.335–1.104), P=0.102]; mOS (23.5 vs. 13.1 months, HR =0.441 (95% CI: 0.203–0.955), P=0.038) |
(61) |
| Advanced gastric cancer (HER2+) |
Chemotherapy +Trastuzumab |
57 |
Median DpR 56.8%, DpR ≥50% vs. DpR <50%, mPFS (9.8 vs. 4.1 months, P<0.001); mOS (24.7 vs. 12.8 months, P<0.001) |
(62) |
| Advanced gastric cancer (HER2+, n=186, HER2-, n=100) |
HER2 +: Chemotherapy + Trastuzumab HER2-: chemotherapy |
286 |
Her2+: Median DpR 44%; DpR ≥44% vs. <44%, PFS: 14 vs. 5.2 months, HR: 0.22, P<0.0001; OS: 29.7 vs. 11.5 months, HR: 0.24, P<0.0001; Her2-: Median DpR, 24%; DpR ≥24% vs. <24%, PFS: 7.6 vs. 4.5 months, HR 0.63, P=0.01; OS: 14.8 vs. 12.2 months, HR 0.87, P=0.48 |
(63) |
| Advanced gastric cancer |
Chemotherapy |
632 |
DpR cutoff values 36.7% for PFS, 40.0% for OS, DpR moderately predicted PFS [Cτ index 0.697 (95% CI, 0.678–0.717)] and OS [Cτ index 0.644 (95% CI, 0.622–0.663)] |
(64) |
